In 280 patients with moderately severe COPD, adding bisoprolol to usual care did not improve a hierarchical composite of death, admissions, exacerbations, quality of life and FEV1 vs placebo over 2 years (win ratio 0.95, p=0.72); deaths 10% vs 8%.
RCTn = 280
Jenkins et al. Bisoprolol to prevent adverse cardiac events (PACE) in COPD: a multicentre, double-blind, randomised, controlled, phase 3 trial